PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19 th Annual European Neuroendocrine ...

As part of a patient-support program (PSP) for those with neuroendocrine tumors (NETs), Ipsen offers Somatuline Autogel/Somatuline Depot (lanreotide) in a prefilled syringe. The company recently ...

(RTTNews) - Ipsen said that new patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline Autogel/Somatuline Depot or lanreotide. The ...

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline ® Autogel ® (lanreotide injection) 60, 90, and 120 ...

Somatuline Depot (lanreotide) is a brand-name drug prescribed for acromegaly, certain cancers, and carcinoid syndrome in adults. Somatuline Depot is given as a subcutaneous injection by a healthcare ...

PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will invest in a new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

The Food and Drug Administration has given Cipla its stamp of approval for lanreotide injection. The medication is the generic of Ipsen’s Somatuline Depot. It is indicated for the treatment of ...

A total of 9 abstracts presented at the 18th Annual European Neuroendocrine Tumor Society (ENETS) Conference showcasing new data across the patient pathway in neuroendocrine tumors Latest data from ...

Ipsen (Euronext : IPN ; ADR : IPSEY) today announced its decision to set up its own oncology team to commercialize Somatuline ® Depot ® (lanreotide) 120 mg Injection (referred to as Somatuline ®) in ...